ACRV – acrivon therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Acrivon Therapeutics (ACRV) was upgraded by Weiss Ratings from "sell (e+)" to "sell (d-)".
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities [Yahoo! Finance]
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Form ARS Acrivon Therapeutics, For: Dec 31
Form DEFA14A Acrivon Therapeutics,
Form DEF 14A Acrivon Therapeutics, For: Jun 17
Form SCHEDULE 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form 4 Acrivon Therapeutics, For: Apr 22 Filed by: RA Capital Healthcare Fund LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.